Stock Analysis

Biome Australia Limited's (ASX:BIO) Price In Tune With Revenues

When you see that almost half of the companies in the Personal Products industry in Australia have price-to-sales ratios (or "P/S") below 0.8x, Biome Australia Limited (ASX:BIO) looks to be giving off strong sell signals with its 5.2x P/S ratio. However, the P/S might be quite high for a reason and it requires further investigation to determine if it's justified.

View our latest analysis for Biome Australia

ps-multiple-vs-industry
ASX:BIO Price to Sales Ratio vs Industry December 1st 2025
Advertisement

How Has Biome Australia Performed Recently?

Biome Australia could be doing better as it's been growing revenue less than most other companies lately. Perhaps the market is expecting future revenue performance to undergo a reversal of fortunes, which has elevated the P/S ratio. If not, then existing shareholders may be very nervous about the viability of the share price.

Want the full picture on analyst estimates for the company? Then our free report on Biome Australia will help you uncover what's on the horizon.

How Is Biome Australia's Revenue Growth Trending?

In order to justify its P/S ratio, Biome Australia would need to produce outstanding growth that's well in excess of the industry.

If we review the last year of revenue growth, the company posted a terrific increase of 42%. Spectacularly, three year revenue growth has ballooned by several orders of magnitude, thanks in part to the last 12 months of revenue growth. So we can start by confirming that the company has done a tremendous job of growing revenue over that time.

Shifting to the future, estimates from the one analyst covering the company suggest revenue should grow by 40% per year over the next three years. Meanwhile, the rest of the industry is forecast to only expand by 4.8% each year, which is noticeably less attractive.

With this information, we can see why Biome Australia is trading at such a high P/S compared to the industry. It seems most investors are expecting this strong future growth and are willing to pay more for the stock.

The Bottom Line On Biome Australia's P/S

Using the price-to-sales ratio alone to determine if you should sell your stock isn't sensible, however it can be a practical guide to the company's future prospects.

As we suspected, our examination of Biome Australia's analyst forecasts revealed that its superior revenue outlook is contributing to its high P/S. Right now shareholders are comfortable with the P/S as they are quite confident future revenues aren't under threat. Unless these conditions change, they will continue to provide strong support to the share price.

Plus, you should also learn about these 2 warning signs we've spotted with Biome Australia (including 1 which makes us a bit uncomfortable).

Of course, profitable companies with a history of great earnings growth are generally safer bets. So you may wish to see this free collection of other companies that have reasonable P/E ratios and have grown earnings strongly.

Valuation is complex, but we're here to simplify it.

Discover if Biome Australia might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About ASX:BIO

Biome Australia

Engages in the development, commercialization, and marketing of various live biotherapeutics and complementary medicines in Australia and internationally.

Exceptional growth potential with mediocre balance sheet.

Advertisement

Updated Narratives

NI
niteco
TXN logo
niteco on Texas Instruments ·

Engineered for Stability. Positioned for Growth.

Fair Value:US$314.4446.5% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
BE
Bejgal
MNSO logo
Bejgal on MINISO Group Holding ·

MINISO's fair value is projected at 26.69 with an anticipated PE ratio shift of 20x

Fair Value:US$28.1829.5% undervalued
46 users have followed this narrative
3 users have commented on this narrative
0 users have liked this narrative
BE
Bejgal
FVRR logo
Bejgal on Fiverr International ·

Fiverr International will transform the freelance industry with AI-powered growth

Fair Value:US$36.8143.1% undervalued
79 users have followed this narrative
7 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

TH
TheWallstreetKing
MVIS logo
TheWallstreetKing on MicroVision ·

MicroVision will explode future revenue by 380.37% with a vision towards success

Fair Value:US$6098.4% undervalued
109 users have followed this narrative
10 users have commented on this narrative
21 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$250.3929.3% undervalued
939 users have followed this narrative
6 users have commented on this narrative
24 users have liked this narrative
OS
oscargarcia
GOOGL logo
oscargarcia on Alphabet ·

The company that turned a verb into a global necessity and basically runs the modern internet, digital ads, smartphones, maps, and AI.

Fair Value:US$3405.8% undervalued
145 users have followed this narrative
6 users have commented on this narrative
18 users have liked this narrative